Skip to main content
Erschienen in: Medical Oncology 2/2013

01.06.2013 | Original Paper

p73 G4C14-to-A4T14 polymorphisms are positively correlated with triple-negative breast cancer in southwestern China

verfasst von: Xin Zhou

Erschienen in: Medical Oncology | Ausgabe 2/2013

Einloggen, um Zugang zu erhalten

Abstract

p73 gene shares structural and functional similarities to p53 and plays an important role in modulating cell cycle arrest and apoptosis. A common non-coding polymorphism of p73 G4C14-to-A4T14 (rs2273953 and rs1801173) at exon 2 may affect gene expression, thus, it may lead to functional significance. The correlation of this polymorphism with clinicopathologic variables of patients with breast cancer has not been investigated. In this study, single-nucleotide polymorphisms (SNPs) of p73 G4C14-to-A4T14 were genotyped by Sequenom MassArray-iPLEX GOLD System in 170 patients with breast cancer. Data were analyzed via t test, chi-square test, and logistic regression analysis. There was no significant correlation between p73 G4C14-to-A4T14 polymorphisms and the patient characteristics, such as clinical TNM stage, menopausal status, axillary lymph node metastasis, pathological type, estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2). No significant relationship was observed between the p73 G4C14-to-A4T14 polymorphism and p73 protein expression in cancer tissues. The frequency of GC/GC genotype in patients with triple-negative breast cancer (TNBC) was 78.9 %, that of patients with others was 57.6 %, and the difference had statistical significance (χ 2  = 5.74, P = 0.02). p73 G4C14-to-A4T14 polymorphisms were negatively correlated with chemosensitivity for anthracycline-based chemotherapy in breast cancer (P > 0.05). p73 G4C14-to-A4T14 polymorphisms are positively correlated with TNBC, and p73 gene may play a critical role in a novel therapeutic strategy to TNBC. Additional larger studies are required to test these hypotheses.
Literatur
1.
Zurück zum Zitat Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90:809–19.PubMedCrossRef Kaghad M, Bonnet H, Yang A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90:809–19.PubMedCrossRef
2.
Zurück zum Zitat Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 2002;416:560–4.PubMedCrossRef Flores ER, Tsai KY, Crowley D, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 2002;416:560–4.PubMedCrossRef
3.
Zurück zum Zitat Jost CA, Marin MC, Kaelin WG Jr. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature. 1997;389:191–4.PubMedCrossRef Jost CA, Marin MC, Kaelin WG Jr. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature. 1997;389:191–4.PubMedCrossRef
4.
Zurück zum Zitat Mai M, Yokomizo A, Qian C, et al. Activation of p73 silent allele in lung cancer. Cancer Res. 1998;58:2347–9.PubMed Mai M, Yokomizo A, Qian C, et al. Activation of p73 silent allele in lung cancer. Cancer Res. 1998;58:2347–9.PubMed
5.
Zurück zum Zitat Yokomizo A, Mai M, Tindall DJ, et al. Overexpression of the wild type p73 gene in human bladder cancer. Oncogene. 1999;18:1629–33.PubMedCrossRef Yokomizo A, Mai M, Tindall DJ, et al. Overexpression of the wild type p73 gene in human bladder cancer. Oncogene. 1999;18:1629–33.PubMedCrossRef
6.
Zurück zum Zitat Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumors. Nature. 2000;404:99–103.PubMedCrossRef Yang A, Walker N, Bronson R, et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumors. Nature. 2000;404:99–103.PubMedCrossRef
7.
Zurück zum Zitat Takahashi H, Ichimiya S, Nimura Y, et al. Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res. 1998;58:2076–7.PubMed Takahashi H, Ichimiya S, Nimura Y, et al. Mutation, allelotyping, and transcription analyses of the p73 gene in prostatic carcinoma. Cancer Res. 1998;58:2076–7.PubMed
8.
9.
Zurück zum Zitat Peters MA, Janer M, Kolb S, et al. Germline mutations in the p73 gene do not predispose to familial prostate-brain cancer. Prostate. 2001;48:292–6.PubMedCrossRef Peters MA, Janer M, Kolb S, et al. Germline mutations in the p73 gene do not predispose to familial prostate-brain cancer. Prostate. 2001;48:292–6.PubMedCrossRef
10.
Zurück zum Zitat Li Q, Athan ES, Wei M, et al. TP73 allelic expression in human brain and allele frequencies in Alzheimer’s disease. BMC Med Genet. 2004;5:14–22.PubMedCrossRef Li Q, Athan ES, Wei M, et al. TP73 allelic expression in human brain and allele frequencies in Alzheimer’s disease. BMC Med Genet. 2004;5:14–22.PubMedCrossRef
11.
Zurück zum Zitat Chen X, Sturgis EM, Etzel CJ, et al. p73 G4C14-to-A4T14 polymorphism and risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never smokers and never drinkers. Cancer. 2008;113:3307–14.PubMedCrossRef Chen X, Sturgis EM, Etzel CJ, et al. p73 G4C14-to-A4T14 polymorphism and risk of human papillomavirus-associated squamous cell carcinoma of the oropharynx in never smokers and never drinkers. Cancer. 2008;113:3307–14.PubMedCrossRef
12.
Zurück zum Zitat De Feo E, Persiani R, La Greca A, et al. A case-control study on the effect of p53 and p73 gene polymorphisms on gastric cancer risk and progression. Mutat Res. 2009;675:60–5.PubMedCrossRef De Feo E, Persiani R, La Greca A, et al. A case-control study on the effect of p53 and p73 gene polymorphisms on gastric cancer risk and progression. Mutat Res. 2009;675:60–5.PubMedCrossRef
13.
Zurück zum Zitat Umar M, Upadhyay R, Khurana R, et al. Role of p53 and p73 genes polymorphisms in susceptibility to esophageal cancer: a case control study in a northern Indian population. Mol Biol Rep. 2012;39:1153–62.PubMedCrossRef Umar M, Upadhyay R, Khurana R, et al. Role of p53 and p73 genes polymorphisms in susceptibility to esophageal cancer: a case control study in a northern Indian population. Mol Biol Rep. 2012;39:1153–62.PubMedCrossRef
14.
Zurück zum Zitat Deng B, Liu F, Wei Y, et al. Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of hepatocellular carcinoma in a Chinese population. Tumour Biol. 2013;34:293–9.PubMedCrossRef Deng B, Liu F, Wei Y, et al. Association of a p73 exon 2 G4C14-to-A4T14 polymorphism with risk of hepatocellular carcinoma in a Chinese population. Tumour Biol. 2013;34:293–9.PubMedCrossRef
15.
Zurück zum Zitat Wang Z, Sturgis EM, Guo W, et al. Association of combined p73 and p53 genetic variants with tumor HPV16-positive oropharyngeal cancer. PLoS ONE. 2012;7:e35522.PubMedCrossRef Wang Z, Sturgis EM, Guo W, et al. Association of combined p73 and p53 genetic variants with tumor HPV16-positive oropharyngeal cancer. PLoS ONE. 2012;7:e35522.PubMedCrossRef
16.
Zurück zum Zitat Ryan BM, McManus R, Daly JS, et al. A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma. Br J Cancer. 2001;85:1499–503.PubMedCrossRef Ryan BM, McManus R, Daly JS, et al. A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma. Br J Cancer. 2001;85:1499–503.PubMedCrossRef
17.
Zurück zum Zitat Hu Z, Miao X, Ma H, et al. Dinucleotide polymorphism of p73 gene is associated with a reduced risk of lung cancer in a Chinese population. Int J Cancer. 2005;114:455–60.PubMedCrossRef Hu Z, Miao X, Ma H, et al. Dinucleotide polymorphism of p73 gene is associated with a reduced risk of lung cancer in a Chinese population. Int J Cancer. 2005;114:455–60.PubMedCrossRef
18.
Zurück zum Zitat Zhou X, Wu C. Association of p73 polymorphisms with genetic susceptibilities to breast cancer: a case-control study [J]. Med Oncol. 2012;29:3216–21.PubMedCrossRef Zhou X, Wu C. Association of p73 polymorphisms with genetic susceptibilities to breast cancer: a case-control study [J]. Med Oncol. 2012;29:3216–21.PubMedCrossRef
19.
Zurück zum Zitat Huang XE, Hamajima N, Katsuda N, et al. Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer. 2003;10:307–11.PubMedCrossRef Huang XE, Hamajima N, Katsuda N, et al. Association of p53 codon Arg72Pro and p73 G4C14-to-A4T14 at exon 2 genetic polymorphisms with the risk of Japanese breast cancer. Breast Cancer. 2003;10:307–11.PubMedCrossRef
20.
Zurück zum Zitat Choi JE, Kang HG, Chae MH, et al. No association between p73 G4C14-to-A4T14 polymorphism and the risk of lung cancer in a Korean population. Biochem Genet. 2006;44:543–50.PubMedCrossRef Choi JE, Kang HG, Chae MH, et al. No association between p73 G4C14-to-A4T14 polymorphism and the risk of lung cancer in a Korean population. Biochem Genet. 2006;44:543–50.PubMedCrossRef
21.
Zurück zum Zitat Hamajima N, Matsuo K, Suzuki T, et al. No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett. 2002;181:81–5.PubMedCrossRef Hamajima N, Matsuo K, Suzuki T, et al. No associations of p73 G4C14-to-A4T14 at exon 2 and p53 Arg72Pro polymorphisms with the risk of digestive tract cancers in Japanese. Cancer Lett. 2002;181:81–5.PubMedCrossRef
22.
Zurück zum Zitat Wang L, Gao R, Yu L. Combined analysis of the association between p73 G4C14-to-A4T14 polymorphisms and cancer risk. Mol Biol Rep. 2012;39:1731–8.PubMedCrossRef Wang L, Gao R, Yu L. Combined analysis of the association between p73 G4C14-to-A4T14 polymorphisms and cancer risk. Mol Biol Rep. 2012;39:1731–8.PubMedCrossRef
23.
Zurück zum Zitat Yu XJ, Fang F, Xie J, et al. Relationship between TP73 polymorphism (G4C14-A4T14) and cancer risk: a meta-analysis based on literatures. Gene. 2011;484:42–6.PubMedCrossRef Yu XJ, Fang F, Xie J, et al. Relationship between TP73 polymorphism (G4C14-A4T14) and cancer risk: a meta-analysis based on literatures. Gene. 2011;484:42–6.PubMedCrossRef
24.
Zurück zum Zitat Liu F, Liu L, Li B, et al. p73 G4C14-A4T14 polymorphism and cancer risk: a meta-analysis based on 27 case-control studies. Mutagenesis. 2011;26:573–81.PubMedCrossRef Liu F, Liu L, Li B, et al. p73 G4C14-A4T14 polymorphism and cancer risk: a meta-analysis based on 27 case-control studies. Mutagenesis. 2011;26:573–81.PubMedCrossRef
25.
Zurück zum Zitat Hu Y, Jiang L, Zheng J, et al. Association between the p73 exon 2 G4C14-to-A4T14 polymorphism and cancer risk: a meta-analysis. DNA Cell Biol. 2012;31:230–7.PubMedCrossRef Hu Y, Jiang L, Zheng J, et al. Association between the p73 exon 2 G4C14-to-A4T14 polymorphism and cancer risk: a meta-analysis. DNA Cell Biol. 2012;31:230–7.PubMedCrossRef
26.
Zurück zum Zitat Thorleifsson G, Walters GB, Hewitt AW, et al. Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma. Nat Genet. 2010;42:906–9.PubMedCrossRef Thorleifsson G, Walters GB, Hewitt AW, et al. Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma. Nat Genet. 2010;42:906–9.PubMedCrossRef
27.
Zurück zum Zitat Shi Y, Xiang P, Li L, Shen M. Analysis of 50 SNPs in CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2 by MALDI-TOF mass spectrometry in Chinese Han population. Forensic Sci Int. 2011;207:183–7.PubMedCrossRef Shi Y, Xiang P, Li L, Shen M. Analysis of 50 SNPs in CYP2D6, CYP2C19, CYP2C9, CYP3A4 and CYP1A2 by MALDI-TOF mass spectrometry in Chinese Han population. Forensic Sci Int. 2011;207:183–7.PubMedCrossRef
28.
Zurück zum Zitat Millis MP. Medium-throughput SNP genotyping using mass spectrometry: multiplex SNP genotyping using the iPLEX-Gold assay. Methods Mol Biol. 2011;700:61–76.PubMedCrossRef Millis MP. Medium-throughput SNP genotyping using mass spectrometry: multiplex SNP genotyping using the iPLEX-Gold assay. Methods Mol Biol. 2011;700:61–76.PubMedCrossRef
29.
Zurück zum Zitat Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109:1721–8.PubMedCrossRef Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. 2007;109:1721–8.PubMedCrossRef
30.
Zurück zum Zitat Wolff A, Hammond M, Schwartz J, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18–43.PubMed Wolff A, Hammond M, Schwartz J, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2007;131:18–43.PubMed
31.
Zurück zum Zitat Wolff A, Hammond M, Schwartz J, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45.PubMedCrossRef Wolff A, Hammond M, Schwartz J, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–45.PubMedCrossRef
32.
Zurück zum Zitat Lee KE, Hong YS, Kim BG, et al. p73 G4C14 to A4T14 polymorphism is associated with colorectal cancer risk and survival. World J Gastroenterol. 2010;16(35):4448–54.PubMedCrossRef Lee KE, Hong YS, Kim BG, et al. p73 G4C14 to A4T14 polymorphism is associated with colorectal cancer risk and survival. World J Gastroenterol. 2010;16(35):4448–54.PubMedCrossRef
33.
Zurück zum Zitat Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRef Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRef
34.
Zurück zum Zitat Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008;26:778–85.PubMedCrossRef Rastogi P, Anderson SJ, Bear HD, et al. Preoperative chemotherapy: updates of national surgical adjuvant breast and bowel project protocols B-18 and B-27. J Clin Oncol. 2008;26:778–85.PubMedCrossRef
35.
Zurück zum Zitat Haber DA, Fearon ER. The promise of cancer genetics. Lancet. 1998;351:1–8.CrossRef Haber DA, Fearon ER. The promise of cancer genetics. Lancet. 1998;351:1–8.CrossRef
36.
Zurück zum Zitat Pfeifer D, Arbman G, Sun XF. Polymorphism of the p73 gene in relation to colorectal cancer risk and survival. Carcinogenesis. 2005;26:103–7.PubMedCrossRef Pfeifer D, Arbman G, Sun XF. Polymorphism of the p73 gene in relation to colorectal cancer risk and survival. Carcinogenesis. 2005;26:103–7.PubMedCrossRef
37.
Zurück zum Zitat Arfaoui AT, Kriaa LBM, El Hadj OEA, et al. Association of a p73 exon 2 GC/AT polymorphism with colorectal cancer risk and survival in Tunisian patients. Virchows Arch. 2010;457:359–68.PubMedCrossRef Arfaoui AT, Kriaa LBM, El Hadj OEA, et al. Association of a p73 exon 2 GC/AT polymorphism with colorectal cancer risk and survival in Tunisian patients. Virchows Arch. 2010;457:359–68.PubMedCrossRef
38.
Zurück zum Zitat Liu L, Wu C, Wang Y, et al. Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival. J Thorac Oncol. 2011;6:1793–800.PubMedCrossRef Liu L, Wu C, Wang Y, et al. Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival. J Thorac Oncol. 2011;6:1793–800.PubMedCrossRef
39.
Zurück zum Zitat Lööf J, Pfeifer D, Adell G, et al. Significance of an exon 2 G4C14-to-A4T14 polymorphism in the p73 gene on survival in rectal cancer patients with or without preoperative radiotherapy. Radiother Oncol. 2009;92:215–20.PubMedCrossRef Lööf J, Pfeifer D, Adell G, et al. Significance of an exon 2 G4C14-to-A4T14 polymorphism in the p73 gene on survival in rectal cancer patients with or without preoperative radiotherapy. Radiother Oncol. 2009;92:215–20.PubMedCrossRef
40.
Zurück zum Zitat Li H, Yao L, Ouyang J, et al. Association of p73 G4C14-to-A4T14(GC/AT)polymorphism with breast cancer survival. Carcinogenesis. 2007;28:372–7.PubMedCrossRef Li H, Yao L, Ouyang J, et al. Association of p73 G4C14-to-A4T14(GC/AT)polymorphism with breast cancer survival. Carcinogenesis. 2007;28:372–7.PubMedCrossRef
41.
Zurück zum Zitat Rakha EA, Chan S. Metastatic triple-negative breast cancer. Clin Oncol (R Coll Radiol). 2011;23:587–600.CrossRef Rakha EA, Chan S. Metastatic triple-negative breast cancer. Clin Oncol (R Coll Radiol). 2011;23:587–600.CrossRef
42.
Zurück zum Zitat Irwin MS, Kondo K, Marin MC, et al. Chemosensitivity linked to p73 function. 2003;3:403–10. Irwin MS, Kondo K, Marin MC, et al. Chemosensitivity linked to p73 function. 2003;3:403–10.
43.
Zurück zum Zitat Yuan P, Miao XP, Zhang XM, et al. Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms. Zhonghua Zhong Liu Za Zhi. 2006;28:107–10.PubMed Yuan P, Miao XP, Zhang XM, et al. Association of the responsiveness of advanced non-small cell lung cancer to platinum-based chemotherapy with p53 and p73 polymorphisms. Zhonghua Zhong Liu Za Zhi. 2006;28:107–10.PubMed
44.
Zurück zum Zitat Liu K, Jiang L, Zhou X. Association of p73 G4C14-to-A4T14 polymorphism at exon 2 with the response of human lung adenocarcinoma cell lines to chemotherapy. Cell Biol Int. 2010;34:185–8.PubMedCrossRef Liu K, Jiang L, Zhou X. Association of p73 G4C14-to-A4T14 polymorphism at exon 2 with the response of human lung adenocarcinoma cell lines to chemotherapy. Cell Biol Int. 2010;34:185–8.PubMedCrossRef
45.
Zurück zum Zitat Tiwary R, Yu W, Sanders BG, et al. α-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73 [J]. Breast Cancer Res. 2011;13:R1.PubMedCrossRef Tiwary R, Yu W, Sanders BG, et al. α-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73 [J]. Breast Cancer Res. 2011;13:R1.PubMedCrossRef
46.
Zurück zum Zitat Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin [J]. Cancer Res. 2010;70:7970–80.PubMedCrossRef Hastak K, Alli E, Ford JM. Synergistic chemosensitivity of triple-negative breast cancer cell lines to poly(ADP-Ribose) polymerase inhibition, gemcitabine, and cisplatin [J]. Cancer Res. 2010;70:7970–80.PubMedCrossRef
Metadaten
Titel
p73 G4C14-to-A4T14 polymorphisms are positively correlated with triple-negative breast cancer in southwestern China
verfasst von
Xin Zhou
Publikationsdatum
01.06.2013
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 2/2013
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-013-0515-x

Weitere Artikel der Ausgabe 2/2013

Medical Oncology 2/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.